Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03697980 · ClinicalTrials.gov registry record

Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform

A clinical trial, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

Completed
Registry status
136
Enrollment target

NCT03697980: Completed study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

NCT03697980 is a clinical trial that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 136 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03697980 has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

COMPLETED
Registry status
136 participants
Enrollment target

Study Summary

Medtronic is sponsoring the Apogee study to further enhance scientific understanding of the implant procedure, optimized blood pressure management, and anticoagulation/ antiplatelet therapy in patients receiving a Medtronic HeartWare™ Ventricular Assist Device (HVAD™) for destination therapy. The Apogee study is conducted within Medtronic's Product Surveillance Platform.

Primary Outcome

Freedom from event is the probability (expressed as a percent of 100) the participant did not have a major adverse event during 12 months post implant via the Kaplan-Meier method. Participants that did not have a major adverse event were censored at the time of last follow-up in Apogee or their end of study at 12 months post implant, whichever occurred first. Major adverse events are defined to be occurrence of infection, bleeding, device malfunction, CT confirmed stroke, or death. Infection, b

Interventions

  • DEVICE HeartWare Ventricular Assist Device

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2019-01-17
Est. Completion 2022-02-10

What the finished NCT03697980 record still lists

NCT03697980 is an observational study that tracks outcomes without assigning an intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which HeartWare Ventricular Assist Device is the first listed.

NCT03697980 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03697980 about?

NCT03697980 is a clinical study titled "Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform". Medtronic is sponsoring the Apogee study to further enhance scientific understanding of the implant procedure, optimized blood pressure management, and anticoagulation/ antiplatelet therapy in patients receiving a Medtronic HeartWare™ Ventricular Assist Device (HVAD™) for destination therapy. The A...

What is the current status of trial NCT03697980?

This trial is currently completed. The enrollment target is 136 participants. The study started on 2019-01-17. Estimated completion is 2022-02-10.

What interventions are being tested in trial NCT03697980?

The interventions under investigation include: HeartWare Ventricular Assist Device (DEVICE).

Who is sponsoring clinical trial NCT03697980?

This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01555892 · 136 participants · Phase 1

    Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • NCT03216525 · 136 participants · Phase 3

    Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

  • NCT04476901 · 136 participants · Phase 2

    Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

  • NCT04603898 · 136 participants · NA

    Oxalate Formation From Ascorbic Acid

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03697980, the US trial registry maintained by the National Library of Medicine. NCT03697980 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.